Consistent with previous reports and unlike in cutaneous melanomas, only a small proportion of patients had BRAF mutations, limiting the treatment options with BRAF/MEK inhibitors.3,4 cKIT mutations were observed 14% and NRAS mutations in 13%; 2 patients were found to have a mutation in SF3B1, a mutation that was recently found to be more prevalent in VVMs and may be associated with worse outcome.22 Here, NRAS is linked to cutaneous melanoma.